Amgen Monthly Obesity Treatment MariTide Achieves Continuous Weight Loss at 52 Weeks

Amgen will present key data for MariTide, its investigational monthly obesity and Type 2 diabetes treatment, at the American Diabetes Association's 85th Scientific Sessions. The presentation will showcase 52-week efficacy and safety data from Phase 2 studies, showing significant weight loss without plateauing in patients with and without Type 2 diabetes. MariTide represents a breakthrough as the first monthly or less frequently dosed peptide-antibody conjugate for obesity treatment. The company will also present new Repatha data regarding lipid-lowering therapy benefits in Type 1 diabetes patients. Amgen will host an investor webcast on June 23, 2025, at 4:30 p.m. CDT to discuss the MariTide program. The scientific sessions will feature additional presentations on cardiovascular efficacy and lipid-lowering therapy patterns from the FOURIER and VESALIUS-REAL studies.

https://www.stocktitan.net/news/AMGN/amgen-s-phase-2-maritide-data-to-be-presented-at-the-american-ja1x5x8nabic.html